A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS—Individuals (n = 476) with HbA1c (A1C) 7.5–10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma glucose targets of ≤6.0 mmol/l (≤108 mg/dl). Outcomes assessed included A1C, percentage achieving A1C ≤7.0%, risk of hypoglycemia, and body weight. RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C ≤7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was −1.58 (P < 0.001). CONCLUSIONS—Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 diabetes achieves guideline-recommended A1C values in most people with aggressive titration. Insulin detemir compared with NPH insulin achieves this with reduced hypoglycemia and less weight gain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The decrease in A1C from triple therapy was greater at 6 months than that of conventional therapy and the superiority was maintained at 3 years.1061”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1061]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648
Research works printed but not linked: 1
- Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 66:193–201, 2004 · DOI · Paper page
Cited by
Items 401–500 of 627
Oishi, M., Abe, N., Yokoyama, H., Kuribayashi, N., Tomonaga, O., Matoba, K., & Kobayashi, M. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000245 · Cited by 6
Yamashiro, K., Ikeda, F., Fujitani, Y., Watada, H., Kawamori, R., & Hirose, T. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00025.x · Cited by 6
Implementación de la estrategia basal plus en la práctica clínica
Alfaro, A. Á. M., Soidán, F. J. G., Guisasola, F. Á., Jl, B. L., Laureano, F. C. S., Zornoza, P. C., Viñau, F. L., Marco, A., Pérez-Lázaro, A., Pérez-Maraver, M., et al. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65007-7 · Cited by 8
Jiang, H. H., Ni, X., Huster, W. J., & Heilmann, C. R. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2014.919939 · Cited by 6
Zilov, A. V., Naggar, N. E., Shah, S. N., Shen, C., & HADDAD, J. A. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.06.003 · Cited by 6
One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
Evans, M., Morgan, A. R., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01061-7 · Cited by 7
Otsuka, S. H. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1228 · Cited by 6
Mathieu, C., & Robbrecht, S. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00841.x · Cited by 6
Insulin Therapy in Type 2 Diabetes
Wyne, K. L., & Mora, P. F. (2007) · Endocrine Research · doi:10.1080/07435800701743836 · Cited by 6
Jakobsen, M., Dalsgaard, M., Hørmann, M., & Møller, D. V. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-21 · Cited by 6
Ghosh, S. K., Unnikrishnan, A. G., Saboo, B., Kesavadev, J., Aravind, S. R., Bajaj, S., Rajput, R., Seshadri, K., Verma, N., Gupta, A., et al. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.045 · Cited by 7
Wheeler, M. D., Pérez, M. B., Lo, F.-S., Liang, B., Lunsford, A., Thórisdóttir, Ó., & Zuckerman‐Levin, N. (2018) · European Journal of Pediatrics · doi:10.1007/s00431-018-3205-z · Cited by 6
Treatment of Diabetes: A Clinical Update on Insulin Trials
LeRoith, D. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(09)60005-3 · Cited by 6
Modern basal insulin analogs: An incomplete story
Singh, A. K., & Gangopadhyay, K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.140239 · Cited by 6
Breum, L., Almdal, T., Eiken, P., Lund, P., & Christiansen, E. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.154 · Cited by 6
The hospital pharmacist: an integral part of the hyperglycaemic management team
Szumita, P. M. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01040.x · Cited by 6
Optimizing treatment strategies with insulin glargine in Type 2 diabetes
Owens, D. R. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.29 · Cited by 5
Therapie mit oralen Antidiabetika und/oder Insulin im höheren Alter?
Siegmund, T., & Schumm‐Draeger, P. (2010) · Der Diabetologe · doi:10.1007/s11428-010-0593-8 · Cited by 5
Detemir (Levemir): modern paradigms of insulin therapy
Руяткина, Л. А., & Sorokin, M. (2013) · Problems of Endocrinology · doi:10.14341/probl201359456-64 · Cited by 5
Pharmacotherapies for Diabetes Management: An Update for the Practicing Clinician
Meneghini, L., & Hirsch, I. B. (2006) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2007.01.003 · Cited by 7
Rezaei, S., Taheri, A., Taheri, S., Kasirzadeh, S., Fatemi, B., & Sorato, M. M. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2078700 · Cited by 5
When a unit of insulin is not a unit: Detemir dosing and insulin cost in type 2 diabetes mellitus
Johnson, C. K., & Shimshi, M. (2009) · Insulin · doi:10.1016/s1557-0843(09)80017-1 · Cited by 5
Patient perceptions of insulin detemir as reported through patient telephone surveys
Kerney, D. L., Paradis, D., & Brunton, S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x219508 · Cited by 5
Khamseh, M. E., HADDAD, J. A., Yang, W., Zilov, A. V., Bech, O. M., & Hasan, M. I. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0033-z · Cited by 5
Insulin Detemir and Basal Insulin Therapy
Russell-Jones, D. L. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)80003-x · Cited by 5
RSSDI guidelines for management of type 2 diabetes mellitus in older adults
Jagadeesha, A., Viswanathan, V., Agarwal, S., Maheshwari, A., Virmani, A. K., Nagendra, L., Amarnath, A., Chawla, M. S., Jethwani, P., Parikh, R. M., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01613-8 · Cited by 4
Basal insulin analogues--a review of recent data on efficacy and safety.
John, M. (2011) · PubMed · Cited by 6
Khamseh, M. E., Prusty, V., Latif, Z. A., González-Gálvez, G., Dieuzeide, G., & Zilov, A. V. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0054-2 · Cited by 5
Levine, J. P. (2008) · Journal of Women s Health · doi:10.1089/jwh.2007.0396 · Cited by 7
Pfohl, M., Dippel, F. W., Kostev, K., Fuchs, S., & Kotowa, W. (2011) · Health Outcomes Research in Medicine · doi:10.1016/j.ehrm.2011.02.001 · Cited by 4
Soewondo, P., Mohamed, M., Jain, A., Sy, R. A., & Khoo, C. M. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(13)70004-4 · Cited by 4
Schwartz, X., Porter, B. A., Gilbert, M. P., Sullivan, A., Long, B., & Lentz, S. A. (2023) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2023.04.018 · Cited by 5
The Transition from Oral Agents to Combination Insulin/Oral Therapy
Riddle, M. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_11 · Cited by 4
Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., & Giugliano, D. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0134 · Cited by 4
Bjekić-Macut, J., Živković, T. B., & Kocić, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0378-4 · Cited by 4
Structure and properties of insulin
Gupta, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820234-0.00004-4 · Cited by 5
Simon, A. C. R., Bolli, G. B., Dain, M., Wang, E., & Holleman, F. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.007 · Cited by 4
Holleman, F., de Vries, J. H., & Hoekstra, J. B. L. (2006) · PubMed · Cited by 4
The role of insulin detemir in overweight type 2 diabetes management
Soran, H. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4326 · Cited by 5
Griffin, S. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.679959 · Cited by 4
Gundgaard, J., Christensen, T., & Thomsen, T. L. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.04.004 · Cited by 4
Practical Approaches to Insulin Therapy
Gavin, J. R. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707301212 · Cited by 4
Ligthelm, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.630998 · Cited by 4
Davidson, J. A., & Koenen, C. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.06.013 · Cited by 4
The when and how of insulin initiation in type 2 diabetes
Liebl, A. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x162836 · Cited by 4
Addition of Insulin to Oral Therapy in Type 2 Diabetes
Ilag, L. L., Martin, S., & Jacober, S. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmc073240 · Cited by 4
Nardi, E., Prastaro, M., Santoro, C., Gallo, L., Simeoli, L., Fontanarosa, S., Paolillo, S., Gargiulo, P., Esposito, G., & Filardi, P. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104033 · Cited by 3
Hirsch, I. B., Schneider, D., King, A., Polonsky, W. H., Reid, T., Shubrook, J. H., Verderese, C. A., Wallace, J. I., & Riddle, M. C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2763 · Cited by 3
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc08-zb01 · Cited by 4
Caporale, J., Pichón-Rivière, A., Beratarrechea, A. G., Schulz-Hausmann, C. V., & Augustovski, F. (2014) · Value in Health Regional Issues · doi:10.1016/j.vhri.2014.02.007 · Cited by 3
Differenzierte Insulintherapie des Typ-2-Diabetes
Liebl, A. (2008) · Der Diabetologe · doi:10.1007/s11428-008-0248-1 · Cited by 3
A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes
Battise, D. M. (2013) · Clinical Diabetes · doi:10.2337/diaclin.31.4.166 · Cited by 4
Malek, R., Arbouche, Z., Dahaoui, A., & Bachaoui, M. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(13)70015-9 · Cited by 3
Intensifying Treatment of Type 2 Diabetes Mellitus: Adding Insulin
Peters, K. R. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.54s · Cited by 4
Echtay, A. S., Andari, E., Atallah, P., Moufarrege, R., & Nemr, R. (2017) · Ethnicity & Disease · doi:10.18865/ed.27.1.45 · Cited by 3
Insulin Pharmacodynamics, Pharmacokinetics, and Insulin Regimens
Kelkar, S., Muley, S., & Ambardekar, P. (2019) · Springer eBooks · doi:10.1007/978-981-13-7705-1_11 · Cited by 3
Fanelli, C. G., Lucidi, P., Bolli, G. B., & Porcellati, F. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_22 · Cited by 3
Gough, S. C. L., & Narendran, P. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch29 · Cited by 3
Pérez, A., & Mendoza, L. C. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2015.12.004 · Cited by 5
Mimouni, S., Faraoun, K., Nouri, N., & Serouti, A. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.04.005 · Cited by 3
Insulin biobetters and biosimilars in clinical practice
Home, P. (2023) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715231173770 · Cited by 5
Self-citationTajiri, Y., Kawano, S., Hirao, S., Oshige, T., Iwata, S., Ono, Y., Inada, C., Akashi, T., Hayashi, H., Sato, Y., et al. (2014) · International Scholarly Research Notices · doi:10.1155/2014/639489 · Cited by 4
Insulin and New Insulin Analogues with Focus on Type 2 Diabetes
Madsbad, S. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_7 · Cited by 3
The vexed question of hypoglycaemia and health economics
Home, P. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12266 · Cited by 3
Self-citationHypoglycemia and insulin treatment
Febo, F., Molinari, C., & Piatti, P. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03345405 · Cited by 3
How to Obtain Appropriate Type 2 Diabetes Control in the First 180 Days of Treatment Initiation
Kuritzky, L., Epstein, B. J., & Lavernia, F. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2140 · Cited by 3
Insulin detemir: a better basal insulin for the management of diabetes?
King, A. B. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.1.15 · Cited by 3
Parkner, T., Laursen, T., Chen, J., Møller, M. K., Thomsen, H. F., Jørgensen, C., Smedegaard, J., Lauritzen, T., & Christiansen, J. S. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100514 · Cited by 3
Treat early, treat appropriately
Liebl, A., Rutten, G. E. H. M., & Abraira, C. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60003-4 · Cited by 3
Which basal insulin should be used in patients with type 2 diabetes mellitus?
Clore, J. N., & Thurby-Hay, L. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0057-8 · Cited by 3
Banerjee, S., Maji, D., & Baruah, M. P. (2013) · PubMed · Cited by 3
CROMER, S. J., Wexler, D. J., & Kazemian, P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108825 · Cited by 5
Swinnen, S. G. H. A., Holleman, F., Hoekstra, J. B. L., & Vries, H. D. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006383 · Cited by 3
Home, P. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12842 · Cited by 3
Self-citationUnderstanding insulin dose deviations in people with type 2 diabetes receiving telemonitoring
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Vestergaard, P., & Hangaard, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.10.001 · Cited by 2
Chien, M.-N., Lee, C., Liu, S.-C., Chen, W.-C., Leung, C.-H., & Wang, C. (2015) · International journal of gerontology · doi:10.1016/j.ijge.2015.05.016 · Cited by 2
Tratamiento combinado de la diabetes mellitus tipo 2
Mata‐Cases, M. (2008) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(08)70768-0 · Cited by 2
Wollenhaupt, D., Wolters, J., Aziz, M. S. A. E., & Nauck, M. A. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003296 · Cited by 2
What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms
Freeman, J. S., & Horton, E. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31826fc5e5 · Cited by 2
Thurston, M. M., Galdo, J. A., & Bourg, C. A. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.1.20 · Cited by 2
Pan, C., Han, P., Ji, L., Ji, Q., Lu, J., Lin, J., Liu, J., Su, B., Shi, J., & Wang, P. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12179 · Cited by 2
Variability in Insulin Action: Mechanisms, Implications, and Recent Advances
(2007) · The Internet Journal of Family Practice · doi:10.5580/173f · Cited by 3
Chow, E., & Heller, S. R. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch5 · Cited by 2
Zalevskaya, A. G., Verbovaya, N. I., Родионова, Т. И., Vikulova, O. K., & Shestakova, M. V. (2010) · Diabetes Mellitus · doi:10.14341/2072-0351-5685 · Cited by 2
Akhtar, S., Wangnoo, S., Ghosal, S., Shetty, R., & Tripathi, S. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.139239 · Cited by 2
Susan, S.-F. G., Clark, L., Dacenko-Grawe, L., Devi, R., Diaz, J., Javadi, M., & Salinas, H. (2011) · InTech eBooks · doi:10.5772/23705 · Cited by 3
Dudzińska, M., Kurowska, M., Tarach, J. S., Malicka, J. E., & Nowakowski, A. M. (2011) · Clinical Diabetology · Cited by 5
Intensifying Treatment in Poorly Controlled Type 2 Diabetes Mellitus: Case Reports
Tibaldi, J. M. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.024 · Cited by 2
Bando, Y., Ishikura, K., Kanehara, H., Aoki, K., Hisada, A., Toya, D., & Tanaka, N. (2013) · Diabetology International · doi:10.1007/s13340-013-0124-0 · Cited by 2
Patient and Physician Barriers to Instituting Insulin Therapy: A Case-Based Overview
Shaefer, C. F. (2007) · Insulin · doi:10.1016/s1557-0843(07)80070-4 · Cited by 4
Belhadj, M., Roula, D., Malek, R., Lezzar, A., Mimouni, S., & Zinaï, S. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70424-8 · Cited by 2
Soidán, F. J. G. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.01.002 · Cited by 2
Bolli, G. B., Deeb, L. C., Garg, S. K., Leahy, J. L., Mazze, R. S., Owens, D. R., Riddle, M. C., Southerland, P., & Strock, E. S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0179 · Cited by 2
Análisis de costes del tratamiento de la diabetes mellitus tipo 2 con insulina glargina o detemir
Guisasola, F. Á., Mauricio, D., Coscolín, T. G., Nicolás, L. B., & Rubio‐Terres, C. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)66009-7 · Cited by 2
Management of Type 2 Diabetes Mellitus with Basal-Prandial Insulin Therapy: A Case-Based Review
Davis, S. N. (2007) · Insulin · doi:10.1016/s1557-0843(07)80040-6 · Cited by 2
Aspectos prácticos en la insulinización del paciente anciano con diabetes
Díaz, M. S. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65004-1 · Cited by 3
Insulin Initiation During a 20-Minute Office Visit: Part 1: Setting the Scene
Valentine, V. (2010) · Diabetes Spectrum · doi:10.2337/diaspect.23.3.188 · Cited by 2
Insulin intensification for people with type 2 diabetes: a practical approach
Fulcher, G. (2010) · Australasian Medical Journal · doi:10.4066/amj.2010.466 · Cited by 2
Veneman, T. F., Storms, F., Eland, I. A., & Bouter, P. (2012) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2012.21016 · Cited by 2
The role of insulin analogs in type 2 diabetes in the rural community
Nelson, S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802467502 · Cited by 2
Metadata
- Authors
- Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group
- Affiliations
- Aarhus University Hospital (DK)
- Leicester Royal Infirmary (GB)
- Out-Patient Clinic, NZOZ Eskulap, Gniewkowo, Poland
- Out-Patient Clinic, Novo Nordisk, Bagsværd, Denmark
- Novo Nordisk (Denmark) (DK)
- Newcastle University (GB)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 29
- Issue
- 6
- Pages
- 1269-1274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2149194615
- Cited by
- 627
- References
- 36
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 31 · 2014: 44 · 2013: 59 · 2012: 55
- FWCI
- 48.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin detemir, NPH insulin, basal insulin, type 2 diabetes, insulin-naive patients, oral glucose-lowering agents, adjunctive therapy, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain
- MeSH terms
- Insulin Detemir, Administration, Oral, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Weight Gain, Body Mass Index, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.